Financial Data and Key Metrics Changes - Q4 revenue was $109.7 million, up 15% year over year [10] - Q4 adjusted EBITDA was $16.4 million, reflecting a significant increase from the previous year [10] - Q4 average healthcare services clients reached $4,341, an increase of $104 from the prior quarter and $379 from the prior year [10] - Q4 total revenue per AhSE was $25,266, up 5% year over year [10] - Q4 operating cash flow was positive at $16.3 million, up $19.3 million year over year [10] - Q4 free cash flow was positive at $9.2 million, up $20.1 million year over year [10] - Cash position improved to $84.2 million as of January 31, up $2.5 million from October 31, 2024 [11] Business Line Data and Key Metrics Changes - The Appresia platform was used in approximately 14% of patient visits across the United States, equating to around 170 million sites [9] - Strong growth was noted in network solutions, with expectations for similar market conditions in 2026 as in 2025 [18][19] Market Data and Key Metrics Changes - The company is monitoring macroeconomic factors closely, including consumer confidence and Medicaid changes, but has not seen significant impacts on business as of now [66][68] Company Strategy and Development Direction - The company aims to continue generating positive free cash flow while investing in long-term profitable revenue growth [11] - The revenue outlook for fiscal year 2026 is maintained at a range of $472 million to $482 million, with adjusted EBITDA expected between $78 million and $88 million [12] - The company is focused on leveraging AI and automation to improve productivity and drive business growth [32][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining growth despite potential macroeconomic challenges, emphasizing a strong operational foundation [66][70] - The company is committed to capital allocation strategies that prioritize durable and profitable growth, considering both organic and inorganic opportunities [70][72] Other Important Information - The company has not made any acquisitions in fiscal year 2025, but previous acquisitions are contributing to growth [75] - The company is excited about the rollout of new products that enhance patient engagement and medication adherence [8][49] Q&A Session Summary Question: What is the potential for gross margin expansion? - Management indicated that mix is a significant driver of gross margin, with expectations for higher growth in certain revenue lines contributing to expansion [16][18] Question: How are market conditions expected to change in 2026? - Management expects market conditions in 2026 to be similar to those in 2025 [19] Question: Can you explain the postscript engagement product? - The product operates on an impression-based model, leveraging data to remind patients about prescriptions [24][25] Question: What impact did the calendar have on revenue per AhSE? - Management noted that calendar factors, including holidays and weather, significantly impacted Q4 performance [30] Question: What progress has been made in leveraging AI? - Management reported positive real-time impacts from AI applications, particularly in forecasting and productivity improvements [34] Question: How is the company positioned in the competitive landscape? - Management noted improved close rates and a beneficial position as a market leader amidst new entrants [42] Question: What is the strategy for capital deployment in 2026? - The company will continue to prioritize capital allocation for durable growth, considering both organic and inorganic opportunities [70][72]

Financial Performance - Total revenue for Q4 fiscal 2025 was $109.7 million, representing a 15% year-over-year increase[7] - Fiscal 2025 total revenue reached $419.8 million, an 18% increase year-over-year[7] - Total revenues for the three months ended January 31, 2025, increased to $109.681 million, up 15.5% from $95.005 million in the same period of 2024[22] - Subscription and related services revenue rose to $51.793 million, a 13.5% increase from $45.653 million year-over-year[22] - Payment processing fees grew to $24.676 million, reflecting a 5% increase compared to $23.508 million in the prior year[22] Profitability Metrics - Adjusted EBITDA for Q4 was $16.4 million, compared to negative $3.5 million in the same period last year[7] - Adjusted EBITDA for the three months ended January 31, 2025, was $16,373, compared to a loss of $3,461 for the same period in 2024[34] - Free cash flow for Q4 was $9.2 million, compared to negative $10.9 million in the same period last year[7] - Free cash flow for the fiscal year ended January 31, 2025, was $8,292, a significant improvement from a negative $57,475 in the previous year[37] - The company reported a net loss of $58.5 million for fiscal 2025, improved from a net loss of $136.9 million in fiscal 2024[7] - Net loss for the fiscal year ended January 31, 2025, was $(58.527) million, a significant reduction from $(136.885) million in the previous fiscal year[22] - The company reported a net loss of $6,390 for the three months ended January 31, 2025, compared to a net loss of $30,646 for the same period in 2024[34] Client Metrics - Average number of healthcare services clients (AHSCs) was 4,341 in Q4, up 10% year-over-year[7] - The company anticipates AHSCs to reach approximately 4,500 in fiscal 2026[9] - The average number of healthcare services clients (AHSCs) increased to 4,341 in Q1 2025 from 3,962 in Q1 2024, representing a growth of 9.6%[40] - Total revenue per AHSC for the fiscal year ended January 31, 2025, was $99,884, up from $98,944 in the previous year, indicating a growth of 0.9%[40] Cash and Liquidity - Cash and cash equivalents as of January 31, 2025, were $84.2 million, providing sufficient flexibility for future growth[10] - Cash and cash equivalents at the end of the period were $84.220 million, slightly down from $87.520 million a year earlier[26] - The company reported a net cash provided by operating activities of $16.256 million for the three months ended January 31, 2025, compared to a net cash used of $(3.078) million in the same period of 2024[26] Future Outlook - The outlook for fiscal 2026 revenue is projected to be between $472 million and $482 million[8] - Adjusted EBITDA for fiscal 2026 is expected to range from $78 million to $88 million[9] Operating Expenses - Operating loss for the three months ended January 31, 2025, improved to $(7.612) million from $(29.578) million in the same quarter of 2024[22] - GAAP operating expenses for the three months ended January 31, 2025, totaled $93,411, down from $100,696 in the same period of 2024, a decrease of 7.8%[39] - Stock-based compensation expense for the fiscal year ended January 31, 2025, was $66,975, compared to $71,613 in 2024, a reduction of 6.2%[39] Asset and Liability Overview - Total assets increased to $388.415 million as of January 31, 2025, compared to $370.326 million in the previous year[20] - Total liabilities rose to $123.607 million, up from $118.877 million year-over-year[20] Development Costs - Capitalized internal-use software development costs for the fiscal year ended January 31, 2025, were $15,380, down from $19,291 in 2024, a decrease of 20.0%[37] Payment Volume - Patient payment volume reached $1,080 million in Q1 2025, compared to $977 million in Q1 2024, reflecting an increase of 10.5%[41] - The payment facilitator volume percentage remained stable at 82% for both Q1 2025 and Q1 2024[41]

Company Overview - Phreesia (PHR) shares increased by 5.6% to $30.01 in the last trading session, with a higher-than-average trading volume, compared to a 4.9% gain over the past four weeks [1] - The company is recognized for its leadership, as Sally Thayer, Vice President of Product Management, was named to The Software Report's list of the Top 50 Women Leaders in Software of 2024, marking the seventh consecutive year a female leader from Phreesia has received this honor [2] Financial Performance - Phreesia is expected to report a quarterly loss of $0.19 per share, reflecting a year-over-year improvement of 66.1%, with anticipated revenues of $108.91 million, up 14.6% from the same quarter last year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Phreesia operates within the Zacks Medical Info Systems industry, which includes other companies like Pulmonx Corporation (LUNG), whose shares also saw a 5.3% increase to $7.38 in the last trading session, with a 4.3% return over the past month [4] - Pulmonx's consensus EPS estimate for its upcoming report has remained unchanged at -$0.43, representing a year-over-year change of -19.4% [5]

Core Viewpoint - Phreesia's stock has shown significant performance, increasing by 16.4% over the past month and reaching a 52-week high of $29.36, outperforming the broader medical sector and medical information systems industry [1][2]. Financial Performance - Phreesia has consistently exceeded earnings expectations, reporting an EPS of -$0.25 against a consensus estimate of -$0.29 in its last earnings report [2]. - For the current fiscal year, Phreesia is projected to have an EPS of -$1.10 with revenues of $419.04 million, reflecting a 56.18% change in EPS and a 17.61% change in revenues [3]. - The next fiscal year forecasts an EPS of -$0.38 and revenues of $476.77 million, indicating a year-over-year change of 66.18% in EPS and 13.78% in revenues [3]. Valuation Metrics - Despite reaching a 52-week high, the future valuation metrics of Phreesia need to be assessed to determine if the stock has become overvalued [4]. Zacks Style Scores - Phreesia has a Value Score of D, a Growth Score of A, and a Momentum Score of D, resulting in a combined VGM Score of B [6]. Zacks Rank - Phreesia holds a Zacks Rank of 2 (Buy), supported by rising earnings estimates, suggesting potential for further stock price appreciation [7].

Core Viewpoint - Phreesia (PHR) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which are a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending January 2025, Phreesia is expected to earn -$1.10 per share, representing a 56.2% change from the previous year's reported figure, with a 10.2% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade of Phreesia to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Technical Analysis - Phreesia Inc (PHR) has reached a key technical support level with its 50-day simple moving average crossing above its 200-day simple moving average, forming a "golden cross" [1] - A golden cross is a bullish technical chart pattern indicating potential upward momentum, typically involving the 50-day and 200-day moving averages [2] - The golden cross pattern consists of three stages: a downtrend bottoming out, a crossover of moving averages triggering a positive trend reversal, and continued upward momentum [3] Recent Performance - PHR has gained 11.8% over the past four weeks [4] - The company currently holds a 3 (Hold) rating on the Zacks Rank, suggesting potential for a breakout [4] Earnings Outlook - PHR has a positive earnings outlook with no earnings estimate cuts for the current quarter and 5 upward revisions in the past 60 days [4] - The Zacks Consensus Estimate for PHR has increased [4] Investment Consideration - Investors may consider PHR for potential gains due to its technical indicators and positive earnings estimate revisions [5]

Core Viewpoint - Phreesia (PHR) has shown a significant price increase of 25.5% over the past four weeks, with a mean price target of $29.80 indicating a potential upside of 25% from the current price of $23.84 [1] Group 1: Price Target Insights - The consensus price target is often viewed with skepticism due to analysts' tendency to set overly optimistic targets, which may mislead investors [2][8] - A tight clustering of price targets, indicated by a low standard deviation of $3.30, suggests strong agreement among analysts regarding the stock's price movement [6] - The lowest price estimate is $23, indicating a potential decline of 3.5%, while the highest estimate suggests a 51% increase to $36 [6] Group 2: Earnings Estimates and Analyst Sentiment - The Zacks Consensus Estimate for the current year has increased by 8.6%, reflecting positive sentiment among analysts with no negative revisions [4] - Analysts' growing optimism regarding PHR's earnings prospects is supported by strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [11] - PHR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [12]

Company Overview - Phreesia (NYSE: PHR) provides software solutions for healthcare providers, focusing on registration, scheduling, payments, and clinical support [1] - The software enhances patient intake processes and improves overall patient experiences [1] Recent Performance - Prior to the Q3 2024 earnings report, Phreesia's stock price increased by 21.0% [1] Analyst Background - Dr. Duru, who has been blogging about financial markets since 2000, has extensive experience through various market cycles, including the dot-com bubble, financial crisis, and the coronavirus pandemic [1] - Dr. Duru's blog "One-Twenty Two" offers unique perspectives on financial markets, covering a range of topics including stocks, options, currencies, and Bitcoin [1] - The blog utilizes both technical and fundamental analysis for trading and investing strategies [1]

Phreesia (PHR) shares ended the last trading session 13.9% higher at $21.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.9% loss over the past four weeks.Phreesia scored a strong price increase, driven by investors’ optimism surrounding its impending fiscal 2025 third-quarter results, slated to be released on Dec. 9 after the closing bell. In the fiscal second quarter, Phreesia reached a crucial milestone by ...

Maskot Summary Following my coverage on Phreesia, Inc. (NYSE:PHR) in Jun'24, in which I recommended a buy rating due to my expectation that the business has no issues growing revenue at 20% given that client growth is still strong, this post is to provide an update on my thoughts on the business and stock. I remain buy-rated for PHR as the growth outlook remains solid. New logo adds remain on track to hit FY25 targets, and the increase in transaction size in the current pipeline lends credence to PHR's next ...